# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- Reuters Citing Sources
RBC Capital analyst Conor McNamara maintains QuidelOrtho (NASDAQ:QDEL) with a Outperform and lowers the price target from $8...
QuidelOrtho (NASDAQ:QDEL) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.39 by ...
In addition to his appointment as President and CEO, Blaser will join the Board, effective May 15, 2024, when the Board will be...
Shares of Stryve Foods, Inc. (NASDAQ: SNAX) fell sharply during Tuesday’s session following a fourth-quarter revenue miss.
QuidelOrtho secures FDA approval for QuickVue COVID-19 test, catering to home and medical settings. Despite Savanna RVP4+ assay...
Test Delivers on Company Commitment to Advance the Power of Diagnostics to Empower Patients with Rapid Results in Just 10 Minut...